Knockdown of Nemo‑like kinase promotes metastasis in non‑small‑cell lung cancer.
Adenocarcinoma
/ genetics
Adult
Aged
Aged, 80 and over
Apoptosis
Biomarkers, Tumor
/ genetics
Carcinoma, Non-Small-Cell Lung
/ genetics
Carcinoma, Squamous Cell
/ genetics
Case-Control Studies
Cell Movement
Cell Proliferation
Epithelial-Mesenchymal Transition
Female
Follow-Up Studies
Gene Expression Regulation, Neoplastic
Humans
Lung Neoplasms
/ genetics
Male
Middle Aged
Neoplasm Invasiveness
Prognosis
Protein Serine-Threonine Kinases
/ genetics
Survival Rate
Tumor Cells, Cultured
beta Catenin
/ genetics
Journal
Oncology reports
ISSN: 1791-2431
Titre abrégé: Oncol Rep
Pays: Greece
ID NLM: 9422756
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
18
01
2018
accepted:
03
07
2019
pubmed:
20
7
2019
medline:
25
1
2020
entrez:
20
7
2019
Statut:
ppublish
Résumé
The evolutionarily conserved serine/threonine kinase Nemo‑like kinase (NLK) serves an important role in cell proliferation, migration, invasion and apoptosis by regulating transcription factors among various cancers. In the present study, the function of NLK in human non‑small cell lung cancer (NSCLC) was investigated. Immunohistochemical analysis and western blotting demonstrated that NLK expression was significantly reduced in NSCLC tissues compared with corresponding peritumoral tissues. Statistical analysis revealed that decreased NLK expression was associated with the presence of primary tumors, tumor node metastasis (TNM) staging, differentiation, lymph node metastasis, and E‑cadherin and vimentin expression. Univariate analysis indicated that NLK expression, differentiation, lymph node metastasis, TNM stage, and E‑cadherin and vimentin expression affected the prognosis of NSCLC. Cox regression analyses revealed NLK expression and TNM as independent factors that affected prognosis. Kaplan‑Meier survival analysis revealed that patients with NSCLC and low NLK expression had relatively shorter durations of overall survival. In vitro, NLK overexpression inhibited A549 ncell migration and invasion as determined by wound healing and Transwell migration assays, respectively. Additionally, immunofluorescence staining indicated that downregulation of NLK expression could induce epithelial‑mesenchymal transition in NSCLC. NLK knockdown significantly decreased the expression of the epithelial marker E‑cadherin, and markedly increased that of β‑catenin and the mesenchymal marker vimentin. Furthermore, NLK was reported to directly interact with β‑catenin as determined by a co‑immunoprecipitation assay. Collectively, the results of the present study indicated that decreased NLK expression could promote tumor metastasis in NSCLC.
Identifiants
pubmed: 31322229
doi: 10.3892/or.2019.7226
pmc: PMC6667924
doi:
Substances chimiques
Biomarkers, Tumor
0
CTNNB1 protein, human
0
beta Catenin
0
NLK protein, human
EC 2.7.1.-
Protein Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1090-1100Références
Mol Cell Biol. 2003 Jan;23(1):131-9
pubmed: 12482967
Nat Rev Cancer. 2003 Jun;3(6):453-8
pubmed: 12778135
Biochem Biophys Res Commun. 2003 Aug 22;308(2):227-33
pubmed: 12901858
Nat Rev Mol Cell Biol. 2003 Aug;4(8):657-65
pubmed: 12923528
Oncogene. 2003 Sep 29;22(42):6524-36
pubmed: 14528277
J Biol Chem. 2006 Jul 28;281(30):20749-60
pubmed: 16714285
Nat Cell Biol. 2007 Nov;9(11):1273-85
pubmed: 17952062
Prostate. 2009 Oct 1;69(14):1481-92
pubmed: 19514049
J Biol Chem. 2010 Mar 12;285(11):8122-9
pubmed: 20061393
J Clin Neurosci. 2011 Feb;18(2):271-5
pubmed: 21177110
Nat Rev Clin Oncol. 2011 Feb;8(2):68-70
pubmed: 21278771
Science. 2011 Mar 25;331(6024):1559-64
pubmed: 21436443
Cell. 2011 Oct 14;147(2):275-92
pubmed: 22000009
Int J Gynecol Cancer. 2011 Nov;21(8):1380-7
pubmed: 22027747
PLoS One. 2012;7(6):e39937
pubmed: 22761930
Cell Signal. 2013 Jan;25(1):190-7
pubmed: 23000342
J Thorac Dis. 2012 Dec;4(6):650-4
pubmed: 23205295
J Cancer Res Clin Oncol. 2013 Sep;139(9):1539-49
pubmed: 23857189
Tumour Biol. 2013 Dec;34(6):3995-4000
pubmed: 23857283
J Cell Biochem. 2014 Jan;115(1):81-92
pubmed: 23904219
PLoS One. 2014 May 09;9(5):e96506
pubmed: 24816797
Sci Signal. 2014 Sep 23;7(344):re8
pubmed: 25249658
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Tumour Biol. 2015 Sep;36(9):6701-14
pubmed: 25820824
Oncotarget. 2015 Aug 21;6(24):20145-59
pubmed: 26023737
Mol Cell Biochem. 2015 Dec;410(1-2):1-9
pubmed: 26260052
Oncotarget. 2016 Jan 26;7(4):4871-81
pubmed: 26717042
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
J Pathol. 2016 May;239(1):60-71
pubmed: 27071482
Oncotarget. 2016 May 31;7(22):33152-64
pubmed: 27121204
Oncotarget. 2016 Jul 5;7(27):42513-42526
pubmed: 27285761
Cell. 2016 Jun 30;166(1):21-45
pubmed: 27368099
Drug Des Devel Ther. 2016 Nov 15;10:3737-3746
pubmed: 27895463
Mol Biol Cell. 2017 Jan 15;28(2):346-355
pubmed: 27903773
Int J Cancer. 2017 Apr 1;140(7):1620-1632
pubmed: 27943262
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Mol Cancer. 2017 Jul 17;16(1):124
pubmed: 28716029
Pharmacol Ther. 2018 Feb;182:80-94
pubmed: 28834698
Gynecol Oncol. 2017 Nov;147(2):408-417
pubmed: 28851501
Cancer Res. 2017 Nov 15;77(22):6415-6428
pubmed: 28947416
Cell Death Dis. 2017 Oct 5;8(10):e3066
pubmed: 28981096
Oncotarget. 2017 Jun 9;8(41):69538-69550
pubmed: 29050223
Int J Cancer. 2018 Mar 15;142(6):1252-1265
pubmed: 29071717
Oncotarget. 2017 Aug 24;8(49):85749-85758
pubmed: 29156753
Nat Rev Cancer. 2018 Feb;18(2):128-134
pubmed: 29326430
Cell Rep. 2018 Jan 23;22(4):1016-1030
pubmed: 29386124
Clin Cancer Res. 2018 Apr 15;24(8):1974-1986
pubmed: 29391352
Cell. 1994 Jul 15;78(1):125-36
pubmed: 8033204